Bdbrut-140mg (Ibrutinib Capsule) 140mg

Bdbrut-140mg (Ibrutinib 140mg capsules) is a targeted therapy used in certain blood cancers. This oral medication belongs to the BTK inhibitor class, designed for convenient at-home use. Suitable for ambient storage, it offers a 30-capsule pack for ongoing treatment. Always consult a healthcare professional for personalized guidance.

Strength

140mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

BDR Pharmaceuticals Intl Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ibrutinib 140mg capsules are primarily used to treat certain types of blood cancers, including mantle cell lymphoma and chronic lymphocytic leukemia. It may also be prescribed for other conditions as determined by a healthcare provider. This medication works by targeting specific pathways in cancer cells to slow their growth. Patients often use it when other treatments have not been effective.

Side Effects

Common effects of ibrutinib include mild nausea, fatigue, and bruising. Some users report digestive discomfort or reduced appetite during early treatment. These effects are typically temporary and may lessen as the body adjusts. Regular monitoring helps manage any persistent symptoms.

Precautions & Warnings

Store ibrutinib capsules at room temperature away from moisture and heat. Keep out of reach of children and pets. Inform your doctor about all medications and supplements you take before starting this treatment. Avoid grapefruit products, as they may interact with the medication’s absorption.

Avoid Interactions

Ibrutinib may interact with blood thinners, antifungals, and certain antibiotics. Alcohol use should be discussed with a healthcare provider, as it may worsen side effects. CYP3A inhibitors can increase ibrutinib levels, while CYP3A inducers may reduce its effectiveness. Always review your full medication list with a professional.

References

Frequently Asked Questions

Ibrutinib 140mg is used to treat certain blood cancers like mantle cell lymphoma and chronic lymphocytic leukemia.

Store ibrutinib capsules at room temperature, away from moisture and direct heat.

No, grapefruit products may interact with ibrutinib and should be avoided.

Common side effects include nausea, fatigue, and bruising, which are usually temporary.

No, ibrutinib requires a prescription from a licensed healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.